Semaglutide Cuts Incidence, Recurrence of Alcohol Use Disorder
By Lori Solomon HealthDay Reporter
TUESDAY, June 25, 2024 -- Semaglutide may cut incidence and recurrence of alcohol use disorder (AUD) in patients with obesity, according to a study published online May 28 in Nature Communications.
William Wang, from Case Western Reserve University in Cleveland, and colleagues used electronic health records of 83,825 patients with obesity to examine associations between AUD and semaglutide use.
The researchers found that compared with other antiobesity medications, semaglutide was associated with a 50 to 56 percent lower risk for both the incidence and recurrence of AUD over a 12-month follow-up period. Across gender, age group, race, and in patients with and without type 2 diabetes (T2DM), similar associations were seen. An additional study population of 598,803 patients with T2DM showed similar results.
"In summary, our results find an association between reduced risk for incident and AUD relapse with the prescription of semaglutide in patients with obesity or T2DM," the authors write. "While these findings provide preliminary evidence of the potential benefit of semaglutide in AUD in real-world populations further randomized clinical trials are needed to support its use clinically for AUD."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
Semaglutide May Reduce Craving in Alcohol Use Disorder
FRIDAY, Feb. 28, 2025 -- Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a study published online Feb. 12 in...
Prenatal Alcohol Exposure Linked to Facial Development at Age 6 to 8 Years
THURSDAY, Feb. 13, 2025 -- Prenatal alcohol exposure is associated with facial development, and the associations persist to age 6 to 8 years, according to a study published online...
Dose-Dependent Link Seen for Alcohol, Cirrhosis, Liver Cancer in Patients With Hep B
WEDNESDAY, Jan. 29, 2025 -- For patients with hepatitis B virus, alcohol is associated with dose-dependent increased risks for cirrhosis and hepatocellular carcinoma (HCC)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.